Background and objective: The association between airflow limitation severity and post-operative pulmonary complications (PPCs) among COPD patients undergoing extra-pulmonary surgery is unknown. We evaluated the association between forced expiratory volume in 1 s (FEV 1 ) and PPC in COPD patients undergoing extra-pulmonary surgery. Methods: Using prospective cohort of PPC evaluation for extra-pulmonary surgery, we identified 694 COPD patients who conducted PPC evaluation before extrapulmonary surgery between March 2014 and January 2015 at a tertiary hospital, Seoul, Korea. Results: The overall incidence of PPC was 24.4%. The incidence of PPC in quintiles 1-5 of FEV 1 (% predicted) was 31.4, 25.8, 23.7, 21.6 and 19.7%, respectively (P for trend: 0.019). In fully adjusted multivariable models, the relative risks (RRs, 95% CI) for PPC comparing participants in quintiles 1-4 of FEV 1 (% predicted) with those in quintile 5 were 1.69 (1.03-2.79), 1.41 (0.83-2.37), 1.26 (0.75-2.11) and 1.30 (0.76-2.22), respectively (P for trend: 0.046). The association of severe airflow limitation with respiratory failure and post-operative exacerbations was stronger in participants who did not use bronchodilators compared with those who did. Conclusion: We found a progressive and significant relationship between severity of airflow limitation and the incidence of PPC in COPD patients undergoing extra-pulmonary surgery. Furthermore, perioperative bronchodilator use was associated with a reduced risk
INTRODUCTION
COPD is a progressive inflammatory disease with major impact on the global burden of disease. 1 With nearly three million annual deaths, COPD will become the third leading cause of death worldwide and is associated with significant extra-pulmonary morbidity, poor quality of life and healthcare costs. [1] [2] [3] [4] Since the prevalence of COPD increases sharply with age, increases in life expectancy result in an increasing number of COPD patients. 5, 6 Many of these patients will require surgical treatment at some point in their life and may experience post-operative pulmonary complications (PPCs). 7 COPD is associated with increased risk of PPC, inhospital mortality and length of hospital stay after surgery. [8] [9] [10] Indeed, some risk factors for COPD, 1 such as smoking, age and poor general condition, are also associated with the development of PPC. 11, 12 While COPD patients are at higher risk of PPC, the impact of airflow limitation severity on PPC after extrapulmonary surgery in COPD patients has not been adequately investigated. Furthermore, there are data on the efficacy of bronchodilator therapy in the perioperative management of COPD patients in lung resection surgery, 13, 14 but little is known about the role of perioperative bronchodilator use in the prevention of PPC, especially with respect to post-operative exacerbations after extra-pulmonary surgery in COPD patients.
The objective of this study was thus to investigate the association of airflow limitation severity on the development of PPC in COPD patients after extrapulmonary surgery in a prospective cohort of patients with prospective assessment of PPC. In addition, we sought to determine the association of perioperative bronchodilators use with the risk of PPC in COPD patients undergoing extra-pulmonary surgery.
METHODS
Using the database of the prospective PPC evaluation for extra-pulmonary surgery cohort of Samsung Medical Center in Seoul, Korea, we identified 1013 consecutive COPD patients aged 40 years and older who were seen by respiratory physicians prior to extra-pulmonary surgery between March 2014 and January 2015. We excluded 319 patients because of concomitant bronchial asthma (n = 61), or because the surgery was cancelled (n = 41), or it was performed under local anaesthesia (n = 215) or the patient had intraoperative complications (n = 2). The final number of study participants was 694. This study was approved by the Institutional Review Board of the Samsung Medical Center (IRB No. 2015-07-117), which exempted the requirement for informed consent because only deidentified data routinely collected as part of patient care were accessed.
Prior to surgery, all patients were evaluated for the Preoperative Pulmonary Complications Assessment (PPCA) tool, 11 a risk stratification scoring instrument based on age, American Society of Anaesthesiologists (ASA) physical status classification, smoking status, airflow limitation, serum albumin, chest radiograph findings and surgery data (type of anaesthesia, elective or emergency surgery and surgical site). Items for the PPCA were originally selected based on the American College of Physicians (ACP) guidelines for PPC-related variables in patients undergoing non-cardiothoracic surgery. 10, 12 The presence of bronchiectasis was assessed using chest radiographs or high resolution chest tomography scans. 15 History of malignancy and other co-morbidities was obtained from the electronic medical record.
Preoperative spirometry was performed using a Vmax 22 apparatus (SensorMedics, Yorba Linda, CA, USA) according to American Thoracic Society/European Respiratory Society criteria. 16 Absolute values of forced expiratory volume in 1 s (FEV 1 ) and forced vital capacity (FVC) were obtained and percentage of predicted values for FEV 1 and FVC were calculated using a reference equation obtained in a representative Korean sample. 17 The patients were considered to have COPD if they had a ratio of FEV 1 to FVC < 0.70 and FEV 1 < 80% predicted. 18 General anaesthesia was induced with sodium thiopental or propofol and maintained with volatile agents (sevo-/iso-/desflurane) or propofol. Remifentanil was infused intravenously based on the haemodynamic response of each individual. Vecuronium, rocuronium or cisatracurium was used as a muscle relaxant to facilitate endotracheal intubation and intraoperative muscle relaxation.
During the perioperative period, we performed a lung-expansion manoeuvre with incentive spirometry in all patients 19 and we encouraged deep inspiration, active coughing and sputum expectoration. Bronchodilator use was defined as use of an inhaled long-acting bronchodilator or short-acting bronchodilator during the perioperative period. Pre-arranged post-operative intensive care unit (ICU) care was recommended at the discretion of the respiratory physicians who assessed PPC.
The primary outcome of the study was the development of major PPC, which included respiratory failure, pleural effusion, atelectasis, respiratory infection, pneumothorax or bronchospasm (post-operative exacerbation) within the first 7 post-operative days, as previously defined. 20 We also analysed each PPC separately as secondary outcomes.
For statistical analysis, descriptive statistics were used to summarize the characteristics of participants by quintile of airflow limitation severity based on FEV 1 (% predicted) (cut-off values for quintiles ≤57, 58-64, 65-70, 71-75 and 76-79% predicted). We estimated adjusted relative risks (RRs) and 95% CIs for incident PPC comparing quintiles 1-4 of FEV 1 (% predicted) with the highest quintile using logistic regression and marginally standardized predicted probabilities. 21 The logistic regression models were initially adjusted for age (continuous), sex, body mass index (BMI) (continuous), ASA physical status (<class 2 and ≥class 2) and albumin (continuous) (Model 1). Model 2 further adjusted for current smoking (no, yes) and the presence of bronchiectasis (no, yes) and Model 3 further adjusted for surgical site (dichotomous category of heart, aorta or open abdominal surgery vs other and laparoscopy) because surgical site is known to be the most important predictor of PPC. 1, 7 For testing linear risk trends, we used the quintile rank as a continuous variable in the regression models.
Because of the limited number of secondary outcomes, we compared the lowest quintile of FEV 1 (% predicted) (severe airflow limitation) with the combination of the four highest quintiles for evaluating the association of airflow limitation severity with individual PPC. In addition, effect modification analyses were explored in pre-specified subgroups defined by age (<70 years vs ≥ 70 years), sex (women vs men), BMI (<23 kg/m 2 vs ≥23 kg/m 2 ), ASA physical status (<class 2 vs ≥ class 2), smoking (non-current vs current smoker), preoperative albumin (<4 g/dL vs ≥4 g/dL), bronchiectasis (no vs yes), malignancy (no vs yes), bronchodilator (no use vs use) and type of surgery (heart, aorta or open abdominal surgery vs other and laparoscopy). All reported P-values were two-sided and the significance level was set at 0.05. All analyses were performed using STATA version 13 (StataCorp LP, College Station, TX, USA).
RESULTS
The mean age of study participants was 68.4 years, and 81% of participants were men (Table 1) . At baseline, the proportions of current smokers, patients with bronchiectasis and patients with a history of malignancy were 16.7, 9.4 and 51.7%, respectively. The mean FVC and FEV 1 were 3.13 L (77.6% predicted) and 1.89 L (65.4% predicted), respectively. Compared with participants in quintiles 2-5 of FEV 1 (% predicted), those with severe airflow limitation (quintile 1) were more likely to have an ASA physical status ≥ class 2, to use a bronchodilator, to have emergency surgery and to have lower average levels of BMI and albumin levels.
Bronchodilators were used in 165 (24%) patients and among them, 44 (27%) patients used maintenance long-acting bronchodilators; 17 (10%) patients with long-acting muscarinic antagonists (LAMAs), 10 (7%) with long-acting beta 2 -agonist (LABAs) AE inhaled corticosteroid (ICS) and 17 (10%) with LAMA and LABA AE ICS. The rest of the patients (n = 121, 73%) used shortacting bronchodilators only in the perioperative period; 76 (46%) with short-acting muscarinic antagonists (SAMAs) and short-acting beta 2 -agonist (SABAs), 41 (25%) with SAMA and 4 (2%) with SABA.
The overall incidence of PPC was 24.4% ( Table 2 ). The most common complication was pleural effusion (incidence 16.4%), followed by atelectasis (12.5%) and respiratory failure (6.1%). In a multivariable logistic regression model, the clinical factors associated with increased risk of PPC were older age, lower BMI, current smoker, lower albumin, bronchiectasis and surgical site (Table S1 , Supplementary Information).
The overall incidence of PPC was significantly inversely associated with FEV 1 (% predicted). The incidence of PPC in quintiles 1-5 of FEV 1 (% predicted) was 31.4, 25.8, 23.7, 21.6 and 19.7%, respectively (P for trend: 0.019; Table 2 ). In fully adjusted multivariable models, the RRs (95% CI) for PPC comparing participants in quintiles 1-4 of FEV 1 (% predicted) with those in quintile 5 were 1.69 (1.03-2.79), 1.41 (0.83-2.37), 1.26 (0.75-2.11) and 1.30 (0.76-2.22), respectively (P for trend: 0.046; Table 3 ). In subgroup analyses, the association of FEV 1 (% predicted) with PPC was stronger in older compared with younger participants (P interaction: 0.02), but there were no differences by other clinical subgroups (Fig. 1) . The RR (95% CI) comparing participants in the lowest quintile of FEV 1 (% predicted) with those in quintiles 2-5 for individual PPC are shown in Table 4 . The lowest quintile of FEV 1 (% predicted) group had a significantly increased risk of respiratory failure (RR = 3.05, 95% CI = 1.70-5.45) and of post-operative exacerbations (RR = 12.19, 95% CI = 2.49-59.77). The associations of severe airflow limitation with respiratory failure and post-operative exacerbations were stronger in participants who did not use bronchodilators compared with those who did (Table 5) .
DISCUSSION
In this study of COPD patients undergoing extrapulmonary surgery, we found a progressive and significant relationship between severity of airflow limitation and the incidence of PPC irrespective of other patientor procedure-related factors, including surgical site. This association was evident not only for overall PPC, but also for respiratory failure and post-operative exacerbations, particularly among patients who did not use a bronchodilator during the perioperative period. Our findings suggest that the severity of airflow obstruction is a risk factor for the development of PPC in COPD patients undergoing extra-pulmonary surgery. Furthermore, the use of bronchodilators in the perioperative period may reduce the incidence of PPC, especially for patients with severe airflow limitation, although randomized clinical trials are needed to establish the clinical benefits of bronchodilator use in this setting.
COPD is a well-known independent risk factor for PPC after extra-pulmonary surgery. [8] [9] [10] COPD is characterized by chronic inflammation of the airways and lung tissue as a result of exposure to inhaled irritants such as smoking. 1 Chronic inflammation causes the destruction of lung parenchyma and the narrowing of small airways, leading to ventilation-perfusion mismatching and impaired gas exchange. 1 In addition, increased sputum production and altered mucociliary clearance may cause more frequently post-operative hypoxaemia, bronchospasm and respiratory failure in COPD patients.
The association between airflow limitation and the risk of PPC in COPD patients, however, has only been studied in samples restricted to abdominal or thoracic surgery or with <100 patients. A study of patients undergoing coronary artery bypass grafting reported that severe airflow limitation (FEV 1 < 60% predicted) was associated with increased post-operative mortality, 22 and another study reported that patients with FEV 1 < 61% predicted combined with hypoxaemia had a significantly higher risk of PPC after abdominal surgery compared with patients with a normal respiratory pattern. 23 Finally, a retrospective study of 26 severe and 52 mild-to-moderate COPD patients undergoing thoracic and major abdominal surgery showed similar rates of minor pulmonary complications but higher rates of serious pulmonary complications in severe COPD patients compared with those with mild-to- moderate COPD. 24 Our data add to the literature in two important ways. First, we show that the increase in PPC risk is progressive throughout the range of airflow obstruction in COPD patients. Second, although open abdominal, heart and aortic surgery had a nearly eightfold increased risk of PPC compared with other surgical sites, and a fourfold increased risk compared to laparoscopic abdominal surgery in the present study, we showed that the association persisted even after adjusting for surgical site. In our study, 1.2% of COPD patients developed postoperative exacerbations, a finding that was consistent with a previous report that 1.1% of 523 COPD patients experienced bronchospasm in a prospective randomized clinical trial of general anaesthesia. 25 Furthermore, a large retrospective review showed that the incidence of perioperative exacerbation in asthma patients, who were expected to have a higher incidence of post-operative exacerbation than COPD patients, was 1.7%. 26 Despite the low incidence, our data showed that post-operative exacerbation with respiratory failure was more frequent in patients with severe airflow limitation and this association was stronger in patients who did not use a bronchodilator. In our study, only 24% of the study participants used long-acting or short-acting bronchodilators in the perioperative period. Considering that most patients in our study had mild respiratory symptoms before surgery, the low rate of bronchodilator use seems to reflect real world of underdiagnosis and undertreatment of COPD. 6, 27 This might be also due to the absence of specific guidelines for using bronchodilators to manage COPD during the perioperative period. Thus, shortacting bronchodilator use during perioperative period is recommended at the discretion of the consulting respiratory physician. Further randomized clinical trials would be necessary to confirm the efficacy and safety of bronchodilator use in COPD patients undergoing extra-pulmonary surgery.
There are several limitations to this study. First, this study was performed at a single tertiary hospital. Second, we could only include COPD patients for whom the managing clinician arranged a consultation with respiratory physicians, and as a consequence we may have not included all patients with COPD undergoing extra-pulmonary surgery. Third, COPD was defined based on pre-bronchodilator pulmonary function tests and may have misclassified some patients. 18 However, as we excluded asthma patients, participants with severe airflow limitation in our study had a high probability of having COPD. Our data may be more informative in a real-world clinical setting as patients who undergo surgery do not routinely get postbronchodilator pulmonary function tests. Fourth, because we did not have enough secondary outcomes, we could not perform multivariable analyses of the secondary outcomes such as respiratory infection and post-operative exacerbations. Finally, we did not assess long-term outcomes, including readmission or mortality, which may also vary depending on airflow limitation.
In conclusion, we found a progressive and significant relationship between severity of airflow limitation and the incidence of PPC in COPD patients undergoing extra-pulmonary surgery. We also found that bronchodilator use was associated with a reduced risk of respiratory failure and post-operative exacerbations in patients with severe airflow limitation undergoing extra-pulmonary surgery, a finding that must be confirmed in future randomized clinical trials. 
